Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2022-07-21 Regulatory Filings
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
hTERT US Patent Granted 2 pages 189.0KB
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the granting of a US patent related to the company's hTERT technology. It includes details about the patent number, its expiration, and the technology's application. There is no financial data, no mention of financial results, no regulatory filings, no meeting materials, or any other report type. The document is a regulatory announcement about intellectual property, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a general regulatory announcement about a patent grant, best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other categories.
2022-07-21 English
INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out 3 pages 172.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that INOVIQ has engaged a US-based contract sales team to accelerate the commercial roll-out of its EXO-NET research products. It discusses the business strategy, market potential, and details of the service agreement with Percorso Life Sciences. There are no financial statements, regulatory filings, or detailed financial performance data included. The document is a corporate announcement about a commercial partnership and business development activity rather than a financial report, regulatory filing, or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit any other specific category.
2022-07-20 English
SubB2M US Patent Grant and Program Update 2 pages 162.7KB
Regulatory Filings Classification · 95% confidence The document is an announcement from INOVIQ Limited regarding the granting of a US patent for their SubB2M technology and updates on the development and commercialisation progress of their diagnostic tests. It includes details about the patent, agreements with service providers, and future plans for clinical testing. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate update focused on intellectual property and program progress rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a formal report. The content fits best under a general regulatory announcement category that covers miscellaneous company updates that do not fit other specific categories.
2022-06-30 English
INOVIQ&University of Sydney Present New EXO-NET Data at ISEV 3 pages 528.6KB
Investor Presentation Classification · 95% confidence The document is a detailed announcement of new scientific data presented by INOVIQ and the University of Sydney at the 2022 International Society for Extracellular Vesicles (ISEV) Annual Meeting. It describes research findings on the utility of EXO-NET for On-Bead Analysis of extracellular vesicles using FTIR spectroscopy. The text includes detailed scientific methodology, results, and conclusions from the study, as well as context about the conference and the company. There is no indication that this is a financial report, earnings release, regulatory filing, or management discussion. It is a scientific presentation of research data shared at an annual meeting, which aligns with the definition of an Investor Presentation (IP) or possibly AGM Information (AGM-R). However, since this is a presentation of scientific data at a professional society's annual meeting (not a shareholder meeting), and it is intended to showcase technology and research progress to investors and stakeholders, the best fit is Investor Presentation (IP). The document is substantive and not a brief announcement or a report publication notice, so it is not RPA or RNS. Therefore, the classification is IP with high confidence.
2022-05-26 English
Change of Director's Interest - Philip Powell 3 pages 216.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the interest, and transaction details. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing'. The document length is 3689 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2022-05-15 English
IIQ Investor Presentation 32 pages 3.8MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's technology platforms, products, market overview, financial information, and future prospects. It includes forward-looking statements, market data, product pipeline, and performance metrics. The content is typical of a presentation aimed at investors to provide a comprehensive overview of the company's business and strategy. There is no indication that this is a regulatory filing, earnings release, or annual report. The length is substantial (15,000 characters), and it is not merely an announcement of a report. Therefore, the document fits the category of an Investor Presentation (IP).
2022-05-09 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.